Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | XIAP | P98170 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 7/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237915 | 0.92 | SLC6A3 (0.39) | PDE3BPDE3AABL1ACHESLC6A3 | |
| SCHEMBL16215997 | 0.92 | SLC6A3 (0.39) | PDE3BPDE3AABL1ACHESLC6A3 | |
| SCHEMBL16215977 | 0.91 | CYP11B1 (0.34) | ABL1SLC6A3 | |
| SCHEMBL10237927 | 0.91 | CYP11B1 (0.34) | ABL1SLC6A3 | |
| SCHEMBL10237917 | 0.91 | DHODH (0.35) | ACHESLC6A3MEN1KMT2AMAPT | |
| SCHEMBL10237940 | 0.87 | PDE3B (0.34) | PDE3BPDE3AABL1XIAPCNR2 | |
| SCHEMBL10237906 | 0.86 | NOTUM (0.46) | PDE3BPDE3AMAPTGRM2 | |
| SCHEMBL10238063 | 0.86 | EIF4E (0.35) | MAPTBLMGRM2 | |
| SCHEMBL10237934 | 0.85 | RAB9A (0.40) | ACHESLC6A3MEN1KMT2AMAPT | |
| SCHEMBL10237919 | 0.83 | RAB9A (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176222-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040826-A1 | NOVEL HERBICIDES | DDT, HDHD5, DDC | PDE3B 2615/4885PDE3A 2386/4885ABL1 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.